**Supplemental Table 1.** Factors associated with 1L CT useover time.

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **August to December 2018** | | | **January to June 2019** | | | **July to December 2019** | | |
|  | **Odds ratio** | **95% CI** | **p value** | **Odds ratio** | **95% CI** | **p value** | **Odds ratio** | **95% CI** | **p value** |
| Age category, years  <65  65–75  >75 | ref  1.01  1.01 | –  0.73–1.41  0.70–1.46 | –  0.93  0.95 | ref  0.70  1.03 | –  0.50–0.99  0.72–1.49 | –  0.05  0.87 | ref  0.99  0.78 | –  0.71–1.38  0.52–1.16 | –  0.94  0.22 |
| Gender  Female  Male | ref  0.86 | –  0.65–1.16 | –  0.32 | ref  0.82 | –  0.62–1.09 | –  0.17 | ref  1.02 | –  0.75–1.37 | –  0.92 |
| Race  White  Black  Asian  Other  Unknown | ref  0.93  2.59  1.28  1.66 | –  0.55–1.57  0.87–7.69  0.78–2.10  1.11–2.49 | –  0.78  0.09  0.32  0.01 | ref  1.02  1.45  0.77  0.75 | –  0.63–1.68  0.46–4.62  0.45–1.32  0.47–1.20 | –  0.92  0.53  0.34  0.23 | ref  1.18  1.27  1.02  0.90 | –  0.70–1.97  0.35–4.57  0.63–1.64  0.57–1.42 | –  0.53  0.71  0.94  0.66 |
| Region  South  Northeast  West  Midwest  Puerto Rico  Unknown | ref  0.91  0.94  0.79  0.00  2.12 | –  0.62–1.33  0.59–1.49  0.50–1.22  0.00–NE  0.34–13.06 | –  0.61  0.78  0.28  0.97  0.42 | ref  0.53  0.88  0.81  3.16  1.21 | –  0.35–0.83  0.56–1.40  0.53–1.24  0.80–12.47  0.24–6.24 | –  <0.01  0.60  0.33  0.10  0.82 | ref  0.84  1.07  1.33  0.00  1.11 | –  0.55–1.29  0.67–1.70  0.88–2.02  0.00–NE  0.62–2.01 | –  0.43  0.78  0.18  0.98  0.72 |
| Practice setting  Academic\*  Community | ref  2.47 | –  0.37–16.44 | –  0.35 | ref  1.12 | –  0.20–6.22 | –  0.90 | –  – | –  – | –  – |
| ECOG performance status  0  1  ≥2  Unknown | ref  1.27  0.87  1.17 | –  0.86–1.86  0.55–1.37  0.75–1.84 | –  0.23  0.55  0.48 | ref  0.65  0.82  0.82 | –  0.44–0.95  0.54–1.26  0.53–1.28 | –  0.02  0.37  0.39 | ref  0.87  0.69  0.77 | –  0.59–1.27  0.43–1.10  0.48–1.24 | –  0.47  0.12  0.28 |
| Diagnosis to index date period, months  0–1  1–2  2–3  >3 | ref  1.02  0.90  1.16 | –  0.74–1.41  0.54–1.52  0.75–1.81 | –  0.89  0.70  0.50 | ref  0.81  1.43  1.78 | –  0.58–1.13  0.91–2.24  1.14–2.77 | –  0.21  0.12  0.01 | ref  0.97  1.45  1.14 | –  0.69–1.38  0.91–2.33  0.70–1.84 | –  0.88  0.12  0.60 |
| Smoking status  No history of smoking  History of smoking | ref  1.31 | –  0.76–2.26 | –  0.34 | ref  1.26 | –  0.76–2.11 | –  0.37 | ref  1.43 | –  0.81–2.52 | –  0.22 |
| Histology  Non-squamous  Squamous  Not otherwise specified | ref  2.86  1.08 | –  2.08–3.93  0.57–2.05 | –  <0.01  0.81 | ref  1.88  2.11 | –  1.37–2.60  1.14–3.91 | –  <0.01  0.02 | ref  1.52  1.01 | –  1.08–2.14  0.47–2.16 | –  0.02  0.98 |
| PD-L1 expression  50%–100%  <1%  1%–49%  Unknown | ref  3.46  2.11  2.64 | –  2.28–5.24  1.34–3.31  1.74–4.01 | –  <0.01  <0.01  <0.01 | ref  3.59  2.54  4.42 | –  2.29–5.64  1.60–4.04  2.82–6.92 | –  <0.01  <0.01  <0.01 | ref  2.24  1.30  2.02 | –  1.48–3.39  0.84–2.02  1.32–3.10 | –  <0.01  0.23  <0.01 |
| Brain metastases  Presence  Absence | ref  0.88 | –  0.58–1.33 | –  0.54 | ref  1.02 | –  0.66–1.58 | –  0.93 | ref  0.90 | –  0.60–1.37 | –  0.63 |

\*Practice setting was not included in the July through December 2019 model because it was perfectly identified by Region = “Unknown”.

1L: first-line; CI: confidence interval; CT: chemotherapy; ECOG: Eastern Cooperative Oncology Group; NE: not estimable; PD-L1: programmed death ligand-1.